Logo image of SRDX

SURMODICS INC (SRDX) Stock Fundamental Analysis

NASDAQ:SRDX - Nasdaq - US8688731004 - Common Stock - Currency: USD

29.02  -0.51 (-1.73%)

After market: 29.02 0 (0%)

Fundamental Rating

3

Taking everything into account, SRDX scores 3 out of 10 in our fundamental rating. SRDX was compared to 188 industry peers in the Health Care Equipment & Supplies industry. While SRDX seems to be doing ok healthwise, there are quite some concerns on its profitability. SRDX does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

In the past year SRDX has reported negative net income.
SRDX had a negative operating cash flow in the past year.
The reported net income has been mixed in the past 5 years: SRDX reported negative net income in multiple years.
Of the past 5 years SRDX 4 years had a positive operating cash flow.
SRDX Yearly Net Income VS EBIT VS OCF VS FCFSRDX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M

1.2 Ratios

SRDX has a Return On Assets (-12.17%) which is comparable to the rest of the industry.
The Return On Equity of SRDX (-18.02%) is better than 63.30% of its industry peers.
Industry RankSector Rank
ROA -12.17%
ROE -18.02%
ROIC N/A
ROA(3y)-8.18%
ROA(5y)-4.34%
ROE(3y)-12.06%
ROE(5y)-6.47%
ROIC(3y)N/A
ROIC(5y)N/A
SRDX Yearly ROA, ROE, ROICSRDX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10 -10 -20

1.3 Margins

The Gross Margin of SRDX (73.37%) is better than 85.11% of its industry peers.
In the last couple of years the Gross Margin of SRDX has declined.
The Profit Margin and Operating Margin are not available for SRDX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 73.37%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-4.3%
GM growth 5Y-3.08%
SRDX Yearly Profit, Operating, Gross MarginsSRDX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40 60 80

More info and screens

5

2. Health

2.1 Basic Checks

SRDX does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for SRDX has been increased compared to 1 year ago.
SRDX has more shares outstanding than it did 5 years ago.
SRDX has a worse debt/assets ratio than last year.
SRDX Yearly Shares OutstandingSRDX Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M
SRDX Yearly Total Debt VS Total AssetsSRDX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

2.2 Solvency

SRDX has an Altman-Z score of 6.36. This indicates that SRDX is financially healthy and has little risk of bankruptcy at the moment.
SRDX's Altman-Z score of 6.36 is amongst the best of the industry. SRDX outperforms 83.51% of its industry peers.
A Debt/Equity ratio of 0.27 indicates that SRDX is not too dependend on debt financing.
SRDX's Debt to Equity ratio of 0.27 is in line compared to the rest of the industry. SRDX outperforms 50.53% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.27
Debt/FCF N/A
Altman-Z 6.36
ROIC/WACCN/A
WACC8.99%
SRDX Yearly LT Debt VS Equity VS FCFSRDX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M 100M

2.3 Liquidity

A Current Ratio of 5.14 indicates that SRDX has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 5.14, SRDX is in the better half of the industry, outperforming 75.53% of the companies in the same industry.
SRDX has a Quick Ratio of 3.99. This indicates that SRDX is financially healthy and has no problem in meeting its short term obligations.
With a decent Quick ratio value of 3.99, SRDX is doing good in the industry, outperforming 73.40% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 5.14
Quick Ratio 3.99
SRDX Yearly Current Assets VS Current LiabilitesSRDX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

More info and screens

3

3. Growth

3.1 Past

The earnings per share for SRDX have decreased strongly by -150.89% in the last year.
Looking at the last year, SRDX shows a very negative growth in Revenue. The Revenue has decreased by -14.96% in the last year.
The Revenue has been growing slightly by 4.72% on average over the past years.
EPS 1Y (TTM)-150.89%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-285.71%
Revenue 1Y (TTM)-14.96%
Revenue growth 3Y6.25%
Revenue growth 5Y4.72%
Sales Q2Q%-12.12%

3.2 Future

SRDX is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 45.52% yearly.
SRDX is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 1.17% yearly.
EPS Next Y-68.76%
EPS Next 2Y26.6%
EPS Next 3Y45.52%
EPS Next 5YN/A
Revenue Next Year-6.59%
Revenue Next 2Y-1.58%
Revenue Next 3Y1.17%
Revenue Next 5YN/A

3.3 Evolution

The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
SRDX Yearly Revenue VS EstimatesSRDX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 20M 40M 60M 80M 100M
SRDX Yearly EPS VS EstimatesSRDX Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 0 0.5 -0.5 1 -1

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for SRDX. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for SRDX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SRDX Price Earnings VS Forward Price EarningsSRDX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 -50 -100 -150 -200

4.2 Price Multiples

Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of SRDX indicates a somewhat cheap valuation: SRDX is cheaper than 63.30% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 91.16
SRDX Per share dataSRDX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4 6 8

4.3 Compensation for Growth

SRDX's earnings are expected to grow with 45.52% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y26.6%
EPS Next 3Y45.52%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for SRDX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

SURMODICS INC

NASDAQ:SRDX (5/30/2025, 8:00:00 PM)

After market: 29.02 0 (0%)

29.02

-0.51 (-1.73%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)04-30 2025-04-30/bmo
Earnings (Next)07-29 2025-07-29/bmo
Inst Owners86.57%
Inst Owner Change2.46%
Ins Owners3.35%
Ins Owner Change-0.58%
Market Cap414.99M
Analysts77.78
Price Target43.86 (51.14%)
Short Float %3.47%
Short Ratio3.74
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)27.11%
Min EPS beat(2)-12.46%
Max EPS beat(2)66.67%
EPS beat(4)3
Avg EPS beat(4)32.66%
Min EPS beat(4)-12.46%
Max EPS beat(4)66.67%
EPS beat(8)7
Avg EPS beat(8)175.9%
EPS beat(12)11
Avg EPS beat(12)125.99%
EPS beat(16)15
Avg EPS beat(16)104.28%
Revenue beat(2)0
Avg Revenue beat(2)-13.33%
Min Revenue beat(2)-14.57%
Max Revenue beat(2)-12.08%
Revenue beat(4)1
Avg Revenue beat(4)-5.09%
Min Revenue beat(4)-14.57%
Max Revenue beat(4)7.17%
Revenue beat(8)5
Avg Revenue beat(8)3.61%
Revenue beat(12)8
Avg Revenue beat(12)2.97%
Revenue beat(16)11
Avg Revenue beat(16)2.49%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)-66.38%
EPS NQ rev (3m)-94.67%
EPS NY rev (1m)-47.57%
EPS NY rev (3m)-47.57%
Revenue NQ rev (1m)-9.23%
Revenue NQ rev (3m)-15.18%
Revenue NY rev (1m)-9.54%
Revenue NY rev (3m)-12.52%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 3.41
P/FCF N/A
P/OCF N/A
P/B 3.76
P/tB 9.12
EV/EBITDA 91.16
EPS(TTM)-0.57
EYN/A
EPS(NY)-0.13
Fwd EYN/A
FCF(TTM)-0.52
FCFYN/A
OCF(TTM)-0.37
OCFYN/A
SpS8.5
BVpS7.71
TBVpS3.18
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -12.17%
ROE -18.02%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 73.37%
FCFM N/A
ROA(3y)-8.18%
ROA(5y)-4.34%
ROE(3y)-12.06%
ROE(5y)-6.47%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-4.3%
GM growth 5Y-3.08%
F-Score2
Asset Turnover0.74
Health
Industry RankSector Rank
Debt/Equity 0.27
Debt/FCF N/A
Debt/EBITDA 6.56
Cap/Depr 25%
Cap/Sales 1.75%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.14
Quick Ratio 3.99
Altman-Z 6.36
F-Score2
WACC8.99%
ROIC/WACCN/A
Cap/Depr(3y)37.09%
Cap/Depr(5y)48.03%
Cap/Sales(3y)2.78%
Cap/Sales(5y)3.64%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-150.89%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-285.71%
EPS Next Y-68.76%
EPS Next 2Y26.6%
EPS Next 3Y45.52%
EPS Next 5YN/A
Revenue 1Y (TTM)-14.96%
Revenue growth 3Y6.25%
Revenue growth 5Y4.72%
Sales Q2Q%-12.12%
Revenue Next Year-6.59%
Revenue Next 2Y-1.58%
Revenue Next 3Y1.17%
Revenue Next 5YN/A
EBIT growth 1Y-120.59%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year181.27%
EBIT Next 3Y61.29%
EBIT Next 5YN/A
FCF growth 1Y71.1%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y76.48%
OCF growth 3Y-74.74%
OCF growth 5Y-50.13%